LRIG2 expression and prognosis in non‑small cell lung cancer

Wang,Guangchuan; Wu,Jie; Song,Huijuan

doi:10.3892/ol.2014.2157

LRIG2 expression and prognosis in non‑small cell lung cancer

Authors:
- Guangchuan Wang
- Jie Wu
- Huijuan Song
View Affiliations

Affiliations: Department of Immunology, Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China, Department of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China, Central Laboratory, Liaoning Medical University, Jinzhou, Liaoning 121000, P.R. China
Published online on: May 19, 2014 https://doi.org/10.3892/ol.2014.2157
Pages: 667-672

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human leucine‑rich repeats and immunoglobulin‑like domains 2 (LRIG2) protein has been shown to be of prognostic value in several types of human cancer, however, the expression profiles of LRIG2 have not been described in non‑small cell lung cancer (NSCLC). The present study evaluated the mRNA expression of LRIG2 in tumor specimens obtained from 39 NSCLC patients by SYBR Green quantitative polymerase chain reaction and the protein expression of LRIG2 in formalin‑fixed paraffin sections obtained from 116 NSCLC patients by immunohistochemistry. The correlations between LRIG2 expression and clinicopathological data were analyzed. The patient survival data were collected retrospectively and the possible prognostic value of LRIG2 protein expression was investigated. The results showed that the mRNA expression of LRIG2 was decreased in NSCLC cancer tissues, which was associated with histological subtypes and tumor differentiation status. The protein expression of LRIG2 was only observed in the cytoplasm of the tumor tissue, which conformed to the mRNA expression results. Furthermore, the patients with high LRIG2 cytoplasmic expression showed poor survival times, and the five‑year survival rate for patients with high LRIG2 expression was 27.8%, compared with 38.8% for patients with low expression (P=0.034), indicating that LRIG2 expression levels may have a potential role in the pathogenesis of NSCLC, and also a significant prognostic value. Further studies are required to fully elucidate the exact function of LRIG2 in NSCLC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Saintigny P and Burger JA: Recent advances in non-small cell lung cancer biology and clinical management. Discov Med. 13:287–297. 2012.
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.
4	Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594. 2008.
5	Collins LG, Haines C, Perkel R and Enck RE: Lung cancer: diagnosis and management. Am Fam Physician. 75:56–63. 2007.
6	Nilsson J, Vallbo C, Guo D, et al: Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun. 284:1155–1161. 2001.
7	Holmlund C, Nilsson J, Guo D, et al: Characterization and tissue-specific expression of human LRIG2. Gene. 332:35–43. 2004.
8	Guo D, Holmlund C, Henriksson R and Hedman H: The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics. 84:157–165. 2004.
9	Hedman H and Henriksson R: LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer. 43:676–682. 2007.
10	Thomasson M, Hedman H, Guo D, Ljungberg B and Henriksson R: LRIG1 and epidermal growth factor receptor in renal cell carcinoma: A quantitative RT-PCR and immunohistochemical analysis. Br J Cancer. 89:1285–1289. 2003.
11	Krig SR, Frietze S, Simion C, et al: Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. Mol Cancer Res. 9:1406–1417. 2011.
12	Lindstrom AK, Ekman K, Stendahl U, et al: LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer. 18:312–317. 2008.
13	Tanemura A, Nagasawa T, Inui S and Itami S: LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg. 31:423–430. 2005.
14	Holmlund C, Haapasalo H, Yi W, et al: Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology. 29:242–247. 2009.
15	Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R and Hellberg D: LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol. 49:812–815. 2010.
16	Muller S, Lindquist D, Kanter L, et al: Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. Int J Oncol. 42:247–252. 2013.
17	Guo D, Nilsson J, Haapasalo H, et al: Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1–3) as prognostic indicators in astrocytic tumors. Acta Neuropathol. 111:238–246. 2006.
18	Shimosato Y: Histological typing of lung and pleural tumors (3rd edition, 1999): Malignant epithelial tumors. Nihon Rinsho. 60:123–131. 2002.(In Japanese).
19	Kontos CK, Papadopoulos IN, Fragoulis EG and Scorilas A: Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. Br J Cancer. 102:1384–1390. 2010.
20	Wang B, Han L, Chen R, et al: Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther. 8:1018–1023. 2009.
21	Lindstrom AK, Asplund A and Hellberg D: Correlation between LRIG1 and LRIG2 expressions and expression of 11 tumor markers, with special reference to tumor suppressors, in CIN and normal cervical epithelium. Gynecol Oncol. 122:372–376. 2011.
22	Ghasimi S, Haapasalo H, Eray M, et al: Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression. J Neurooncol. 108:435–441. 2012.
23	Kazmi N, Marquez-Garban DC, Aivazyan L, et al: The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. Lung Cancer Manag. 1:259–272. 2012.
24	Liu B, Zheng Y, Wang TD, et al: Proteomic identification of common SCF ubiquitin ligase FBXO6-interacting glycoproteins in three kinds of cells. J Proteome Res. 11:1773–1781. 2012.
25	Zhang YW, Brognard J, Coughlin C, et al: The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell. 35:442–453. 2009.
26	Zhang H, Yan Q, Xu S, et al: Association of expression of Leucine-rich repeats and immunoglobulin-like domains 2 gene with invasiveness of pituitary adenoma. J Huazhong Univ Sci Technolog Med Sci. 31:520–523. 2011.
27	Wu X, Hedman H, Bergqvist M, et al: Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncol. 51:69–76. 2012.
28	Musacchio M and Perrimon N: The Drosophila kekkon genes: novel members of both the leucine-rich repeat and immunoglobulin superfamilies expressed in the CNS. Dev Biol. 178:63–76. 1996.
29	Eisenstat DD and Gibson SB: RIGging functional outcomes in glioma cells: new insights into LRIG proteins in malignant gliomas. Cancer Biol Ther. 8:1024–1026. 2009.